OPKO Health Q1 revenue down 14% to $149.9M; net loss narrows to $67.6M; signs $225M Labcorp asset sale

OPKO HEALTH, INC.

2025-FY EPS reported -$0.10 vs consensus -$0.07 ▼ miss (-44.3%)

Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.
Signed definitive agreement to sell oncology testing assets to Labcorp for up to $225M ($192.5M at close + $32.5M earnout); expected close H2 2025.
Board authorized additional $100M for stock buyback (total $200M); ~$40.2M repurchased under prior program since July 2024.
Post-quarter: exchanged $159.2M convertible notes for 121.4M shares + $63.5M cash.
Collaboration with Entera Bio for oral GLP-1/glucagon tablet; OPKO purchased 3.7M Entera shares at $2.17/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.